The CYP4502D6*4 and*6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

Basit Öğe Kaydı
dc.authoridSılan, Coşkun/0000-0002-8352-6571
dc.contributor.authorYalcintepe, Sinem
dc.contributor.authorÖzdemir, Öztürk
dc.contributor.authorSılan, Coşkun
dc.contributor.authorOzen, Filiz
dc.contributor.authorUludağ, Ahmet
dc.contributor.authorCandan, Ferhan
dc.contributor.authorSılan, Fatma
dc.date.accessioned2025-01-27T20:29:39Z
dc.date.available2025-01-27T20:29:39Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe cytochrome P450 2D6 (CYP2D6) is a cytochrome P450 enzyme involved in the oxidative biotransformation of the xenobiotics, carcinogens and various clinically important drugs. Patients are evaluated in three sub-groups of extensive (EM), intermediate (IM) and poor metabolizer (PM) phenotypes due to their drug-metabolising ability for the target CYP2D6 gene. Colchicine non-responsive FMF patients were prospectively genotyped for the major CYP2D6 alleles in the current study. Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods. DNA banks isolated from blood-EDTA were retrospectively used in the current patients and results were compared statistically. Increased CYP2D6 *4 and *6 allele frequencies were highly detected in the colchicine non-responsive FMF patients when compared to the responsive group. Results showed the frequencies of major CYP2D6 *1(wild), *3(2637A > delA), *4(G1934A), *5(total gene deletion) and *6(1707T del) alleles in 0.550, 0.042, 0.158, 0.025 and 0.225 for non-responder and 0.880 and 0.120 (CYP2D6*1 and *4) for the responder groups, respectively. Despite small sample size, this study suggests that there is an association between CYP2D6*4 and CYP2D6*6 alleles and drug intoxicants in colchicine non-responder FMF patients.
dc.identifier.doi10.1007/s13318-015-0255-8
dc.identifier.endpage286
dc.identifier.issn0378-7966
dc.identifier.issn2107-0180
dc.identifier.issue3
dc.identifier.pmid25645282
dc.identifier.scopus2-s2.0-84922154006
dc.identifier.scopusqualityQ2
dc.identifier.startpage281
dc.identifier.urihttps://doi.org/10.1007/s13318-015-0255-8
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23004
dc.identifier.volume41
dc.identifier.wosWOS:000376250700009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer France
dc.relation.ispartofEuropean Journal of Drug Metabolism and Pharmacokinetics
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectCYP2D6 polymorphism
dc.subjectColchicine resistance
dc.subjectFMF
dc.subjectPharmacogenetics
dc.titleThe CYP4502D6*4 and*6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu